IRIS PubliCatt

Sora', Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.561
EU - Europa 3.355
AS - Asia 1.301
AF - Africa 41
SA - Sud America 17
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.521
DE - Germania 1.077
SE - Svezia 664
IT - Italia 529
CN - Cina 510
SG - Singapore 414
IE - Irlanda 245
UA - Ucraina 192
FR - Francia 166
ID - Indonesia 164
GB - Regno Unito 159
FI - Finlandia 104
RU - Federazione Russa 97
IN - India 79
TR - Turchia 45
HK - Hong Kong 29
CA - Canada 27
CI - Costa d'Avorio 27
BE - Belgio 24
CZ - Repubblica Ceca 21
IR - Iran 16
NL - Olanda 15
ES - Italia 10
JP - Giappone 9
KR - Corea 9
HU - Ungheria 8
MX - Messico 7
BR - Brasile 6
EG - Egitto 6
PL - Polonia 6
VN - Vietnam 6
AT - Austria 5
AU - Australia 5
CH - Svizzera 5
BZ - Belize 4
CL - Cile 4
EE - Estonia 4
RO - Romania 4
CO - Colombia 3
IL - Israele 3
LI - Liechtenstein 3
LT - Lituania 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
ET - Etiopia 2
MA - Marocco 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
EU - Europa 1
GH - Ghana 1
GR - Grecia 1
HR - Croazia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MC - Monaco 1
MN - Mongolia 1
PA - Panama 1
PH - Filippine 1
TH - Thailandia 1
TW - Taiwan 1
Totale 8.285
Salva come PNG Salva come JPEG
Città #
Chandler 641
Ashburn 391
Singapore 309
Dublin 242
Woodbridge 178
Jacksonville 156
Jakarta 156
San Mateo 136
Dearborn 125
Nanjing 112
Wilmington 108
Fairfield 90
Beijing 88
Houston 88
Ann Arbor 84
Milan 77
Cattolica 70
Moscow 69
Rome 66
Seattle 64
Boston 63
Los Angeles 62
Florence 57
Redmond 57
Princeton 56
Nürnberg 53
Munich 52
Nanchang 51
New York 51
Lancaster 49
Redwood City 49
Marseille 46
Lawrence 41
Bremen 39
Helsinki 34
Izmir 34
Chicago 32
Abidjan 27
Hong Kong 25
Kunming 25
Brussels 24
Norwalk 24
Lappeenranta 23
Boardman 21
Santa Clara 21
Hefei 17
Leawood 17
Pune 17
Toronto 17
Brno 16
Cambridge 16
Mountain View 16
Auburn Hills 15
Hangzhou 15
London 15
Shenyang 15
Guangzhou 14
Shanghai 14
Fremont 13
Hebei 13
Tianjin 13
Jiaxing 12
University Park 12
Frankfurt am Main 11
Changsha 10
San Francisco 9
Zhengzhou 9
Mumbai 8
Philadelphia 8
Washington 8
Amsterdam 7
Bologna 7
Budapest 7
Phoenixville 7
Seoul 7
Augusta 6
Changchun 5
Hanoi 5
Jinan 5
Lanzhou 5
Mexico City 5
North Hollywood 5
Paris 5
Surabaya 5
Tokyo 5
Wuhan 5
Albuquerque 4
Ardabil 4
Arezzo 4
Belize City 4
Bhubaneswar 4
Buffalo 4
Chengdu 4
Clifton 4
Edinburgh 4
Fuzhou 4
Kemerovo 4
Naples 4
Ottawa 4
Phoenix 4
Totale 4.743
Salva come PNG Salva come JPEG
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 355
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 305
Dasatinib first-line: Multicentric Italian experience outside clinical trials 264
Dasatinib first-line: Multicentric Italian experience outside clinical trials 263
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 228
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 148
Correlation between paraproteinaemia and viral reactivation after allo-SCT 142
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 138
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 134
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 128
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 128
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 117
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 116
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 115
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 106
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 105
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 105
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 103
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 103
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 102
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 101
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 100
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 94
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 92
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 91
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 88
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 87
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 86
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 81
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 78
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 76
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 73
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 72
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 71
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 70
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 69
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 68
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 67
Unrelated cord blood transplantation and post-transplant cyclophosphamide 67
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 66
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 66
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 65
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study 64
Unrelated cord blood transplantation and post-transplant cyclophosphamide 64
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 63
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 63
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 62
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 60
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 58
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 58
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 57
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 57
the concomitance of lymphoma and breast carcinoma in the bone 57
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 56
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 56
SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation 54
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 53
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 52
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 52
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 50
Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry 49
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 49
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 49
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 49
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 48
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 48
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 47
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 46
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 45
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 45
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. 45
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 45
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 45
The concomitance of lymphoma and breast carcinoma in the bone 44
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors 43
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 43
Second haploidentical stem cell transplantation for primary graft failure 43
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 41
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 41
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 40
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 40
New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation 39
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 39
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 39
Residual peripheral Blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and durin treatment- free Remission 38
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 37
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 37
Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population 36
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 35
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 35
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. 35
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 35
'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy 34
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 33
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. 32
correction idelalisib exposure before allogenic stem cell transplantation in patients with follicular lymphoma an EBMT survey 31
Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party 31
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 30
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 29
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 29
Totale 7.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.185
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.185
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020670 0 0 0 0 90 110 93 68 57 104 90 58
2020/2021950 362 128 38 44 55 47 45 13 71 17 112 18
2021/2022907 73 39 38 40 65 24 18 139 49 61 177 184
2022/20232.021 253 238 147 255 208 272 95 153 259 39 77 25
2023/20241.268 42 350 55 85 39 146 96 74 26 70 115 170
2024/2025782 99 77 213 171 222 0 0 0 0 0 0 0
Totale 8.521